scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
81 hedge funds and large institutions have $175M invested in scPharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 24 reducing their positions, and 8 closing their positions.
540% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $160K
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
13% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 24
11% more funds holding
Funds holding: 73 → 81 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.45% less ownership
Funds ownership: 83.47% → 78.02% (-5.5%)
18% less capital invested
Capital invested by funds: $213M → $175M (-$37.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$7.54M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.15M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.51M |
| 4 |
TC
Tejara Capital
London,
United Kingdom
|
+$3.76M |
| 5 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$23.5M |
| 2 |
CAC
Cowen and Company
New York
|
-$12.8M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$5.99M |
| 4 |
Morgan Stanley
New York
|
-$5.37M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.73M |
SCPH Hedge Fund Activity: Q4 2023 in Review
81 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2023, worth a combined $175M — down 18% from $213M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SCPH positions and 8 closed out — a net gain of 8 holders — while 27 added to existing stakes and 24 trimmed.
The largest buyer was J. Goldman & Co, adding an estimated $7.54M. The largest seller was RTW Investments, exiting entirely with an estimated $23.5M sold.
- 81 institutional investors held scPharmaceuticals (SCPH) as of Q4 2023, up from 73 in Q3 2023.
- Funds reported $175M of scPharmaceuticals stock for Q4 2023, down 18% quarter-over-quarter.
- 16 funds opened new scPharmaceuticals positions in Q4 2023 and 8 closed out, a net change of +8 holders.
- The largest scPharmaceuticals buyer in Q4 2023 was J. Goldman & Co, an estimated $7.54M added.
- The largest scPharmaceuticals seller in Q4 2023 was RTW Investments, an estimated $23.5M sold.
Based on aggregated 13F filings for Q4 2023.